An all-new COVID-19 vaccine trial is launching in South Australia. Researchers and developers are looking for healthy volunteers to participate in our clinical trial investigating a potential new type of COVID-19 vaccine. Clinical trial platform Evrima has launched the trial as a part of a nationwide push to gain further access to a vaccine. The trial is an opportunity for South Australians to be a part of groundbreaking medical research that could help to raise vaccination rates throughout Australia.
The demand for COVID-19 vaccinations is much greater than the supply of doses available in Australia. Having more choices available is excellent news for health authorities and the Australian and global population.
Several approved/authorised vaccines have been shown to protect against COVID-19 and have been successful in many countries. But it doesn't stop there.
All viruses, including the virus that causes COVID-19, change over time. Some changes may affect the virus's properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures. New variants are being discovered, and so research must continue to protect against them.
This means it's vitally important to be constantly developing potential new vaccines to help fight the virus.
This research project will test an experimental COVID-19 study vaccine, SARS-CoV-2 AS03 Adjuvanted Recombinant Protein Vaccine, containing an "antigen" and an "adjuvant". The antigen is the spike protein copied from the SARS-CoV-2 virus that is made harmless and cannot cause an infection.
It is the same spike protein antigen used in other COVID-19 vaccines that have been authorised in multiple countries. Antigens can trigger the body's defences to produce antibodies that fight disease. Antibodies are proteins in the blood which are part of your immune system. Adjuvants are ingredients added to help a vaccine work better by increasing the immune response.
The trial, being conducted at Fusion Clinical Research clinics, is aimed at South Australians aged 18 to 55 years old, who have not had a COVID jab, and have never had COVID-19. All eligible participants will be paid for their time.
Participation in the study is expected to last up to 55 weeks. This includes:
● 1st vaccination at the clinic
● 2nd vaccination at the clinic, 21 days later
● 6 follow up visits at the clinic
● Regular phone calls
Interested participants can sign up here: http://adelaidecovidstudy.com/
About the trial
The trial is entitled Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (two Monovalent and one Bivalent).
About Evrima
Our mission is to accelerate patient identification and recruitment to help advance medical development. We're driven to reduce the administrative burden on researchers so they can focus on the high-value clinical work required to get new medicines from bench to bedside. We do this by connecting GPs to trials at scale and providing patients trial opportunities in a consumer-friendly way thereby accelerating recruitment timelines and increasing trial enrolment.
Without participants in research we would not have the chance to get new therapies to market and so it is equally important that through technology, we give people and clinicians the knowledge of clinical trials as a care option. Together, we can change the game in clinical trials and get new therapies to those who need them.
About Fusion Clinical Research
Fusion Clinical Research is a division of CMAX Clinical Research based in Adelaide and works with local and international contract research organisations and sponsors including pharmaceutical, biotech, digital health and medical device companies. They have experienced study teams, who operate with a detailed set of SOPs and work instructions under the governance of the CMAX Clinical Research Quality Management team.
